MTOR and cyclic hematopoiesis: As such, CH can compromise the normal working of PI3K/Akt and MAPK/ERK pathways (foremost therapeutic targets in cancer treatment) by suppressing mTOR expression, thus inhibiting autophagic thrust with simultaneous enhancement of apoptosis progression in cancer cells [13].